| Katie Mattingley, MS, CCC-SLP | |
|
100 2nd St E, Suite 322, Whitefish, MT 59937-2410 | |
| (406) 730-3454 | |
| (855) 312-7680 |
| Full Name | Katie Mattingley |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 100 2nd St E, Whitefish, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033653761 | NPI | - | NPPES |
| 1033653761 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SLP-SP-LC-1221 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Katie Mattingley, MS, CCC-SLP Po Box 404, Whitefish, MT 59937-0404 Ph: (208) 859-8903 | Katie Mattingley, MS, CCC-SLP 100 2nd St E, Suite 322, Whitefish, MT 59937-2410 Ph: (406) 730-3454 |
News Archive
In a recently published review article in the journal Drug Discovery Today, scientists have described the utility of human-based microphysiological systems MPSs in understanding the pathophysiology of SARS-CoV-2 infection and developing effective therapeutic interventions. Moreover, they have described the establishment of a global working group to synchronize recent developments around MPSs and COVID-19 research.
Tommorow, February 17, John J. Pippin, M.D., FA.C.C., will testify before Food and Drug Administration (FDA) officials and present a new report detailing how experiments on mice, dogs, and other animals misled scientists and ultimately contributed to a tragic outcome for human patients exposed to Vioxx and other drugs.
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
A new Northwestern Medicine brain-machine technology delivers messages from the brain directly to the muscles - bypassing the spinal cord - to enable voluntary and complex movement of a paralyzed hand. The device could eventually be tested on, and perhaps aid, paralyzed patients.
› Verified 2 days ago
Sarah Briggs, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1305 7th St, Whitefish, MT 59937 Phone: 406-862-3557 | |
Shelby Swant Damaskos, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2006 Hospital Way, Whitefish, MT 59937 Phone: 406-862-9378 Fax: 406-862-9882 | |
Laura Pearce, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 312 Cascade Ct Unit D, Whitefish, MT 59937 Phone: 406-922-7997 | |
Mr. Gregory David Logan, M.S., SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 219 Minnesota Ave, Whitefish, MT 59937 Phone: 407-270-1949 | |
Jasna Stafford, M.A. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2006 Hospital Way, Whitefish, MT 59937 Phone: 406-862-9378 | |
Whitefish Center Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1305 7th St, Whitefish, MT 59937 Phone: 406-862-3557 |